Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCC
(MedPage Today) -- More than 90% of patients with locally advanced basal cell carcinoma (BCC) of the head and neck achieved locoregional control (LRC) with vismodegib (Erivedge) and radiation therapy (RT), a small clinical trial showed.
LRC at...
Source: MedPage Today Radiology - Category: Radiology Source Type: news
More News: Basal Cell Carcinoma | Cancer & Oncology | Carcinoma | Clinical Trials | Radiation Therapy | Radiology | Skin Cancer